3 active not recruiting, 2 not yet recruiting, 2 recruiting, 1 completed. 6 Phase 1, 5 Phase 2, 1 Not applicable.
Follow this condition Literature Review of Transformed Follicular Lymphoma (TFL) trials Research Report on Transformed Follicular Lymphoma (TFL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies MTM-H-001 Injection - Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular | Not applicable | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 69 | 2026-03-01 | 2026-03-17 |
| CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Enrolling by invitation | University of Maryland, Baltimore | 15 | 2024-10-28 | 2026-09-14 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients TC011 - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | TICAROS Co., Ltd. | 98 | 2023-08-03 | 2026-03-16 |
| Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients CRC01, Fludarabine, Cyclophosphamide - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Curocell Inc. | 91 | 2021-03-02 | 2026-07-01 |
| Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy - Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 26 | 2021-02-18 | 2026-10-07 |
| ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) WZTL002-1 (1928T2z CAR-T cells), Cyclophosphamide and Fludarabine lymphodepleting chemotherapy - Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 | Active not recruiting | Malaghan Institute of Medical Research | 30 | 2019-10-11 | 2024-08-21 |
| Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Kite, A Gilead Company | 307 | 2015-04-21 | 2024-06-04 |
Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Recurrence (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoma, Non-Hodgkin (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Lymphoma (7) · Lymphoma, B-Cell (7) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, B-Cell (2)
Cyclophosphamide (4) · fludarabine (3) · 13-valent pneumococcal vaccine (1) · Bendamustine Hydrochloride (1) · Carboplatin (1) · Cisplatin (1) · Dexamethasone (1) · Doxorubicin (1) · Etoposide (1) · Gemcitabine (1) · Ifosfamide (1) · Levetiracetam (1) · Methylprednisolone (1) · Oxaliplatin (1) · Pneumococcal Vaccines (1)
AbelZeta Inc. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Curocell Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Kite, A Gilead Company (1) · Malaghan Institute of Medical Research (1) · Poseida Therapeutics, Inc. (1) · TICAROS Co., Ltd. (1) · University of Maryland, Baltimore (1)
United States (5) · South Korea (2) · Canada (1) · China (1) · France (1) · Germany (1) · Israel (1) · Netherlands (1) · New Zealand (1)
Djordje Atanackovic, MD (1) · Frederick Locke, MD (1) · Ning Li, Ph.D (1) · Robert Weinkove, MBBS, PhD (1) · Simon Heidegger, MD (1) · Yihong Yao, PhD (1)
PMID 34515338, PMID 29226797, PMID 30518502, PMID 32175617, PMID 33035333, PMID 33334730, PMID 34296427, PMID 34310745, PMID 34493319, PMID 34531588, PMID 34628052, PMID 36821768, PMID 38635762, PMID 39240498, PMID 42284198
2015 (1)